Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia
Jorge J. Castillo(Dana-Farber Cancer Institute), Steven P. Treon(Dana-Farber Cancer Institute), Richard R. Furman(Cornell University), Zachary R. Hunter(Harvard University), Ranjana H. Advani(Stanford Medicine), Andrew Keezer(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Joshua Gustine(Boston University), Kirsten Meid(Shaanxi Research Association for Women and Family), Toni Dubeau(Shaanxi Research Association for Women and Family), Guang Yang(Imperial College London), John Allan(Cornell University), Jessica Lam(Stanford University), Lian Xu(Huazhong Agricultural University), Tanya Siddiqi(City Of Hope National Medical Center)
Cited by 11
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k